Clinical significance of serum interferon regulatory factor 1 in rheumatoid arthritis

doi:10.11958/20251530

Abstract

Abstract:

Objective To investigate the clinical significance of serum interferon regulatory factor 1 (IRF1) in rheumatoid arthritis (RA) patients. Methods Thirty patients with RA and 30 healthy individuals (control group) were included in this study. The serum levels of IRF1 and anti-cyclic citrullinated peptide (anti-CCP) antibody were detected by enzyme-linked immunosorbent assay. Assessment questionnaire (HAQ), interleukin-6 (IL-6) and disease activity score (DAS) 28-ESR were collected from the RA patients. Patients with RA received initial methotrexate (MTX) monotherapy (10-20 mg weekly) for 1-3 months. Disease activity was assessed using the DAS28-ESR at weeks 4 and 12, and the treatment regimen was adjusted if necessary. Short-term, low-dose corticosteroids or nonsteroidal anti-inflammatory drugs could be used concomitantly for rapid symptom relief. The serum levels of IRF1 and anti-CCP antibody were compared before and after treatment between the RA group and the control group. Spearman's correlation analysis was used to analyze the correlation between IRF1 and clinical and laboratory indicators of RA patients. The diagnostic value of IRF1 for RA was assessed by receiver operating characteristic (ROC) curve. Results Serum IRF1 and anti-CCP antibody levels were significantly higher in the RA group compared with those of the control group. No significant correlation was found between serum IRF1 concentration and anti-CCP antibodies, ESR, CRP, DAS28-ESR, TJC, SJC, VAS, HAQ, IL-6 and RF (P>0.05). After receiving methotrexate treatment for 4 weeks, the serum IRF1 level of RA patients showed no significant change compared to baseline (P>0.05). By the 12th week, the serum IRF1 level decreased significantly compared with that of treatment for 4 week and pre-treatment (P<0.05). The area under ROC curve (AUC) of IRF1 and anti-CCP antibody combined for RA diagnosis was 0.968 (95%CI:0.924-1.000), which was better than the single diagnosis of IRF1 or anti-CCP antibody (AUC was 0.831 and 0.852, respectively). Conclusion Serum IRF1 level is increased in RA patients. IRF1 has a certain diagnostic value in RA, and the combined diagnostic efficiency with anti-CCP antibody is higher.

Key words: arthritis, rheumatoid, interferon regulatory factor-1, autoantibodies, methotrexate, anti-CCP antibody

CLC Number:

R593.22

Figures/Tables 4

References 15

[1]	薛乐乐, 鄂林宁. 类风湿关节炎相关间质性肺疾病的CT与MRI应用进展[J]. 国际医学放射学杂志, 2023, 46(5):556-561.
	XUE L L, E L N. Research progress of CT and MRI in rheumatoid arthritis-related interstitial lung disease[J]. Int J Med Radiol, 2023, 46(5):556-561. doi:10.19300/j.2023.Z20526.
[2]	FINCKH A, GILBERT B, HODKINSON B, et al. Global epidemiology of rheumatoid arthritis[J]. Nat Rev Rheumatol, 2022, 18(10):591-602. doi:10.1038/s41584-022-00827-y.
[3]	耿研, 谢希, 王昱, 等. 类风湿关节炎诊疗规范[J]. 中华内科杂志, 2022, 61(1):51-59.
	GENG Y, XIE X, WANG Y, et al. The standardized diagnosis and treatment of rheumatoid arthritis[J]. Chin J Intern Med, 2022, 61(1):51-59. doi:10.3760/cma.j.cn112138-20210616-00426.
[4]	海峡两岸医药卫生交流协会风湿免疫病学专业委员会慢病管理学组. 类风湿关节炎慢病管理专家指导建议[J]. 中华内科杂志, 2023, 62(11):1256-1265.
	Chronic Disease Management Group of the Rheumatology and Immunology Committee of the Cross-Strait Medical and Health Exchange Association. Expert recommendations for the chronic disease management of rheumatic arthritis[J]. Chin J Intern Med, 2023, 62(11):1256-1265. doi:10.3760/cma.j.cn112138-20221219-00940.
[5]	LIU J, BERTHIER C C, KAHLENBERG J M. Enhanced inflammasome activity in systemic lupus erythematosus is mediated via type i interferon-induced up-regulation of interferon regulatory factor 1[J]. Arthritis Rheumatol, 2017, 69(9):1840-1849. doi:10.1002/art.40166.
[6]	MAROTTE H, TSOU P S, RABQUER B J, et al. Blocking of interferon regulatory factor 1 reduces tumor necrosis factor α-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein a:role of the nuclear interferon regulatory factor 1-NF-κB-c-jun complex[J]. Arthritis Rheum, 2011, 63(11):3253-3262. doi:10.1002/art.30583.
[7]	ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis,2010, 69(9):1580-1588. doi:10.1136/ard.2010.138461.
[8]	KONDO N, KURODA T, KOBAYASHI D. Cytokine networks in the pathogenesis of rheumatoid arthritis[J]. Int J Mol Sci, 2021, 22(20):10922. doi:10.3390/ijms222010922.
[9]	许文静, 高冬梅, 李慧心, 等. 类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系[J]. 天津医药, 2024, 52(2):193-196.
	XU W J, GAO D M, LI H X, et al. Correlation analysis of serum Chemerin with disease activity and Th17/Treg in patients with rheumatoid arthritis[J]. Tianjin Med J, 2024, 52(2):193-196. doi:10.11958/20230505.
[10]	FUJITA T, SAKAKIBARA J, SUDO Y, et al. Evidence for a nuclear factor(s),IRF-1,mediating induction and silencing properties to human IFN-beta gene regulatory elements[J]. EMBO J, 1988, 7(11):3397-3405. doi:10.1002/j.1460-2075.1988.tb03213.x.
[11]	TADA Y, HO A, MATSUYAMA T, et al. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1[J]. J Exp Med, 1997, 185(2):231-238. doi:10.1084/jem.185.2.231.
[12]	YOSHIDA S, ARAKAWA F, HIGUCHI F, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection:up-regulation of inflammation-associated STAT1,IRF1,CXCL9,CXCL10,and CCL5[J]. Scand J Rheumatol, 2012, 41(3):170-179. doi:10.3109/03009742.2011.623137.
[13]	BONELLI M, DALWIGK K, PLATZER A, et al. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes :JAKinibs suppress the interferon response in RA-FLSs[J]. Exp Mol Med, 2019, 51(7):1-11. doi:10.1038/s12276-019-0267-6.
[14]	郭书婷, 张瑞雪, 延峰. 血清阴性类风湿关节炎3例并文献复习[J]. 风湿病与关节炎, 2022, 11(2):29-32.
	GOU S T, ZHANG R X, YAN F. Three cases of serum negative rheumatoid arthritis and literature review[J]. Arthritis Rheum, 2022, 11(2):29-32. doi:10.3969/j.issn.2095-4174.2022.02.007.
[15]	SOUTO-CARNEIRO M, TÓTH L, BEHNISCH R, et al. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis[J]. Ann Rheum Dis, 2020, 79(4):499-506. doi:10.1136/annrheumdis-2019-216374.

组别	n	IRF1/（μg/L）	抗CCP抗体/（U/mL）
对照组	30	4.145（3.591，4.641）	12.000（8.750，15.000）
RA组	30	6.087（4.844，6.450）	81.200（25.650，466.575）
Z		4.406^＊	4.691^＊

组别	n	IRF1/（μg/L）	抗CCP抗体/（U/mL）
对照组	30	4.145（3.591，4.641）	12.000（8.750，15.000）
RA组	30	6.087（4.844，6.450）	81.200（25.650，466.575）
Z		4.406^＊	4.691^＊

各项指标	参数	r_s	P
ESR/（mm/1 h）	41.433±2.818	-0.060	0.752
CRP/（mg/L）	14.10（7.15，24.70）	-0.124	0.514
DAS28-ESR/分	5.443±0.201	-0.154	0.417
TJC/个	9.870±1.069	0.003	0.987
SJC/个	2.500（2.000，4.250）	-0.074	0.698
疼痛VAS评分/分	5.530±0.358	-0.178	0.347
HAQ/分	9.000（3.750，18.000）	-0.046	0.809
IL-6/（μg/L）	44.495（28.090，59.542）	-0.334	0.071
RF/（IU/mL）	146.500（26.075，408.500）	0.063	0.740

各项指标	参数	r_s	P
ESR/（mm/1 h）	41.433±2.818	-0.060	0.752
CRP/（mg/L）	14.10（7.15，24.70）	-0.124	0.514
DAS28-ESR/分	5.443±0.201	-0.154	0.417
TJC/个	9.870±1.069	0.003	0.987
SJC/个	2.500（2.000，4.250）	-0.074	0.698
疼痛VAS评分/分	5.530±0.358	-0.178	0.347
HAQ/分	9.000（3.750，18.000）	-0.046	0.809
IL-6/（μg/L）	44.495（28.090，59.542）	-0.334	0.071
RF/（IU/mL）	146.500（26.075，408.500）	0.063	0.740

指标	AUC（95%CI）	截断值	敏感度/ %	特异度/ %	约登指数
IRF1	0.831（0.718~0.944）	4.774 μg/L	83.3	80.0	0.633
抗CCP抗体	0.852（0.736~0.969）	21 U/mL	100.0	80.0	0.800
IRF1+抗 CCP抗体	0.968（0.924~1.000）		96.7	96.3	0.900